1. Home
  2. OPRT vs GLUE Comparison

OPRT vs GLUE Comparison

Compare OPRT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPRT
  • GLUE
  • Stock Information
  • Founded
  • OPRT 2005
  • GLUE 2019
  • Country
  • OPRT United States
  • GLUE United States
  • Employees
  • OPRT N/A
  • GLUE N/A
  • Industry
  • OPRT Finance: Consumer Services
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • OPRT Finance
  • GLUE Health Care
  • Exchange
  • OPRT Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • OPRT 312.5M
  • GLUE 308.8M
  • IPO Year
  • OPRT 2019
  • GLUE 2021
  • Fundamental
  • Price
  • OPRT $5.20
  • GLUE $10.05
  • Analyst Decision
  • OPRT Sell
  • GLUE Buy
  • Analyst Count
  • OPRT 2
  • GLUE 2
  • Target Price
  • OPRT $6.00
  • GLUE $13.50
  • AVG Volume (30 Days)
  • OPRT 587.4K
  • GLUE 1.1M
  • Earning Date
  • OPRT 11-11-2025
  • GLUE 11-06-2025
  • Dividend Yield
  • OPRT N/A
  • GLUE N/A
  • EPS Growth
  • OPRT N/A
  • GLUE N/A
  • EPS
  • OPRT N/A
  • GLUE 0.29
  • Revenue
  • OPRT $724,757,000.00
  • GLUE $177,986,000.00
  • Revenue This Year
  • OPRT $26.95
  • GLUE $77.63
  • Revenue Next Year
  • OPRT $5.74
  • GLUE N/A
  • P/E Ratio
  • OPRT N/A
  • GLUE $35.04
  • Revenue Growth
  • OPRT N/A
  • GLUE 2990.57
  • 52 Week Low
  • OPRT $2.50
  • GLUE $3.50
  • 52 Week High
  • OPRT $9.25
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • OPRT 32.92
  • GLUE 68.94
  • Support Level
  • OPRT $5.05
  • GLUE $7.24
  • Resistance Level
  • OPRT $5.63
  • GLUE $11.47
  • Average True Range (ATR)
  • OPRT 0.23
  • GLUE 0.65
  • MACD
  • OPRT -0.06
  • GLUE 0.20
  • Stochastic Oscillator
  • OPRT 12.38
  • GLUE 66.42

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: